Trials / Conditions / Unresectable Rectal Adenocarcinoma

Unresectable Rectal Adenocarcinoma

8 registered clinical trials studyying Unresectable Rectal Adenocarcinoma.

Status	Trial	Sponsor	Phase
Active Not Recruiting	Testing the Addition of Nivolumab to Standard Treatment for Patients With Metastatic or Unresectable Colorecta NCT05308446	National Cancer Institute (NCI)	Phase 2
Active Not Recruiting	LY3214996 and Cetuximab Alone or in Combination With Abemaciclib for the Treatment of Unresectable or Metastat NCT04616183	M.D. Anderson Cancer Center	Phase 1 / Phase 2
Active Not Recruiting	SX-682 and Nivolumab for the Treatment of RAS-Mutated, MSS Unresectable or Metastatic Colorectal Cancer, the S NCT04599140	M.D. Anderson Cancer Center	Phase 1 / Phase 2
Active Not Recruiting	Panitumumab, Regorafenib, or TAS-102, in Treating Patients With Metastatic and/or Unresectable RAS Wild-Type C NCT03992456	Academic and Community Cancer Research United	Phase 2
Terminated	Genetic Testing in Screening Patients With Metastatic or Unresectable Colon or Rectal Cancer for a COLOMATE Tr NCT03765736	Academic and Community Cancer Research United	—
Completed	TAS-102, Irinotecan, and Bevacizumab for the Treatment of Pre-treated Metastatic or Unresectable Colorectal Ca NCT04109924	Roswell Park Cancer Institute	Phase 2
Terminated	Savolitinib in Treating Patients With MET Amplified Metastatic or Unresectable Colorectal Cancer NCT03592641	National Cancer Institute (NCI)	Phase 2
Active Not Recruiting	Encorafenib, Cetuximab, and Nivolumab in Treating Patients With Microsatellite Stable, BRAFV600E Mutated Unres NCT04017650	M.D. Anderson Cancer Center	Phase 1 / Phase 2